Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bausch&Lomb Envision TD

This article was originally published in The Gray Sheet

Executive Summary

Implantable drug delivery system development at firm's Waterford, Ireland facility is expected to yield an eye implant to treat posterior uveitis and diabetic macular edema, B&L announces Feb. 26. Late stage clinical trials using the drug fluocinolone acetonide in combination with the "rice-grain" sized delivery device for the indications in the U.S., Europe and Japan could lead to commercialization in 2004; FDA has granted the device "fast track" status, firm notes. Clinical trials for age-related macular degeneration began in January...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT016166

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel